A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool
Sponsor: Assaf-Harofeh Medical Center
This PHASE2 trial investigates Bone Sarcoma and Chondrosarcoma and is currently ongoing. Assaf-Harofeh Medical Center leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assaf-Harofeh Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.